QLGN · Qualigen Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.1K | - | $105.6K | $17.8K | $33.2K | - | $123.4K | $754.3K | $364.4K | - |
| SG&A | $3.55M | - | $1.89M | $1.39M | $2.49M | - | $1.15M | $986.5K | $1.06M | - |
| Total Operating Expenses | $4.33M | - | $1.43M | $1.68M | $2.72M | - | $1.27M | $1.74M | $1.42M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($4.33M) | - | ($1.43M) | ($1.68M) | ($2.72M) | - | ($1.27M) | ($1.74M) | ($1.42M) | - |
| Interest Expense | - | - | $342.2K | $106.1K | $74.0K | - | $28.0K | $377.4K | $68.0K | - |
| Income Tax | $0 | - | - | - | $35 | - | ($2.2K) | ($1.2K) | $1.8K | - |
| Net Income | ($6.08M) | - | ($2.04M) | ($1.69M) | ($2.65M) | - | ($1.79M) | ($1.58M) | ($2.03M) | - |
| EPS - Basic | ($0.79) | - | ($4.70) | ($1.00) | ($17.60) | - | - | ($0.21) | - | - |
| EPS - Diluted | ($0.79) | - | ($4.68) | ($1.00) | ($17.60) | - | ($4.70) | ($0.21) | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.20M | $19.33M | $38.78M | $331.6K | $30.2K | $1.17M | $401.8K | $590.6K | $1.53M | $401.8K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.48M | $1.26M | $1.28M | $1.40M | $1.53M | $1.57M | $1.64M | $1.85M | $1.80M | $2.22M |
| Current Assets | $23.49M | $30.95M | $43.47M | $3.96M | $2.85M | $4.68M | $2.31M | $534.4K | $1.00M | $1.17M |
| Total Assets | $23.90M | $31.28M | $43.47M | $3.96M | $2.85M | $4.69M | $2.31M | $534.4K | $1.00M | $2.03M |
| Current Liabilities | $2.03M | $3.33M | $4.92M | $5.61M | $2.81M | $2.01M | $4.45M | $4.81M | $4.52M | $4.14M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | $4.14M |
| Stockholders' Equity | $33.1K | $27.95M | $38.55M | $2.68M | $33.1K | $2.68M | ($2.14M) | ($4.28M) | ($3.52M) | ($2.10M) |
| Retained Earnings | ($146.11M) | ($140.03M) | ($129.43M) | ($127.39M) | ($125.71M) | ($123.06M) | ($122.21M) | ($120.41M) | ($118.84M) | ($116.80M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.50M) | - | - | - | ($1.59M) | - | - | - | ($783.6K) | - |
| Investing Cash Flow | ($8.50M) | - | - | - | ($305.0K) | - | - | - | - | - |
| Financing Cash Flow | ($132.0K) | - | - | - | $750.0K | - | - | - | $475.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.4% | - | -4.7% | -42.5% | -92.9% | - | -77.6% | -295.0% | -202.6% | - |
| Return on equity | -18346.8% | - | -5.3% | -62.9% | -7986.3% | - | 83.8% | 36.9% | 57.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 11.57 | 9.30 | 8.83 | 0.71 | 1.01 | 2.33 | 0.52 | 0.11 | 0.22 | 0.28 |
| Quick ratio | 11.57 | 9.30 | 8.83 | 0.71 | 1.01 | 2.33 | 0.52 | 0.11 | 0.22 | 0.28 |
| Cash ratio | 3.05 | 5.81 | 7.88 | 0.06 | 0.01 | 0.59 | 0.09 | 0.12 | 0.34 | 0.10 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -4.2x | -15.9x | -36.8x | - | -45.3x | -4.6x | -20.9x | - |
| Equity multiplier | 721.36 | 1.12 | 1.13 | 1.48 | 85.94 | 1.75 | -1.08 | -0.12 | -0.28 | -0.97 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | 2.03 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -59.1% | - | -12.7% | 3.3% | -91.6% | - | 54.3% | 51.0% | 61.5% | - |
| Net income growth (YoY) | -129.7% | - | -13.6% | -6.9% | -30.2% | - | 50.9% | 54.5% | 47.1% | - |
| EPS growth (YoY) | 95.5% | - | 0.4% | -376.2% | - | - | - | 69.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 0.0% | 943.3% | - | - | - | - | -30.5% | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2022-12-31.
Product / service
$4.98M totalNet Product Sales$4.98M · 100.0%
Peer comparison
Same SIC group: Finance Services
Comparing Qualigen Therapeutics against the 5 most active filers in the same SIC group.